.jpg)
.jpg)
It sounds like you came across a sensational claim—“This one injection will kill cancer”—attributed to billionaire doctor Patrick Soon-Shiong. The reality, however, is much more nuanced. Here’s what’s actually known:
What’s the Claim Based On?
-
A STAT article reports that promotional materials featuring a natural killer (NK) cell therapy implied revolutionary results for cancer treatment. But the data didn’t match the hype. Out of 12 patients in an early-stage trial, only 4 showed any response—and that response was short-lived in three of them. The rest progressed despite treatment. Experts criticized the language as emotional marketing, not scientific fact.STAT
-
The video in question highlighted a patient’s remission, but she was also on standard chemotherapy and steroids—making it unclear whether the NK therapy was effective or not.STAT
What Is NK-92 Therapy?
-
The NK-92 therapy—which is linked to one of Soon-Shiong’s companies, NantKwest—is still in early clinical testing. The available data focuses primarily on safety, not definitive effectiveness.
-
One small Phase 2 trial in Merkel cell carcinoma patients (a rare cancer) was modestly encouraging but remains preliminary. Approval processes have not been completed, and more research is needed.STAT
Bottom Line
-
No credible, peer-reviewed evidence supports the idea that there is a single injection that can eliminate all cancers.
-
The claim appears to come from promotional materials rather than scientifically validated outcomes.
-
Natural killer cell therapies, including NK-92, are still experimental, and their results remain mixed or unverified at this stage.
On Related Controversies: The “Catch-and-Kill” Lawsuit
You might also have heard about legal disputes involving Soon-Shiong:
-
Sorrento Therapeutics alleges that Soon-Shiong’s company acquired an experimental cancer drug called Cynviloq, then halted its development—possibly to protect his existing cancer drug, Abraxane. Sorrento claims breach of contract and fraud, seeking damages exceeding $1 billion.ForbesSTATS&P Global
-
Soon-Shiong has countered, stating that Cynviloq lacked bioequivalence to Abraxane, had manufacturing impurities, and that further development would require restarting clinical trials. He asserts that efforts are still ongoing through other channels.MedscapeForbes
Final Thoughts
-
No injection currently exists—especially from Dr. Soon-Shiong—that can "kill cancer" in a single shot.
-
NK-cell therapies remain in early phases, with limited data and no firm conclusions yet.
-
The surrounding legal battles underscore how complex and sometimes contentious the path from discovery to treatment can be—even for well-publicized figures.
If you'd like, I can walk you through the current stage of NK therapies in clinical trials or provide reliable sources tracking their development. Let me know!
0 Comments:
Post a Comment